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Glioblastomas and brain metastases are highly
proliferative brain tumors with short survival times.
Previously, using 13C-NMR analysis of brain tumors
resected from patients during infusion of
13C-glucose, we demonstrated that there is robust
oxidation of glucose in the citric acid cycle, yet
glucose contributes less than 50% of the carbons
to the acetyl-CoA pool. Here, we show that primary
and metastatic mouse orthotopic brain tumors have
the capacity to oxidize [1,2-13C]acetate and can do
so while simultaneously oxidizing [1,6-13C]glucose.
The tumors do not oxidize [U-13C]glutamine. In vivo
oxidation of [1,2-13C]acetate was validated in
brain tumor patients and was correlated with expres-
sion of acetyl-CoA synthetase enzyme 2, ACSS2.
Together, the data demonstrate a strikingly common
metabolic phenotype in diverse brain tumors that in-
cludes the ability to oxidize acetate in the citric acid
cycle. This adaptation may be important for meeting
the high biosynthetic and bioenergetic demands of
malignant growth.
INTRODUCTION
Malignant brain tumors are among the most intractable prob-
lems in cancer. Glioblastoma (GBM), the most common and
aggressive primary tumor, has a median survival of 16 months.
Despite intense clinical efforts at targeting various signaling
pathways, putative driver mutations, and angiogenesis mecha-Cnisms, no improvement in survival has emerged since 2005,
with the addition of temozolomide to radiation as initial therapy
(Cloughesy et al., 2014; Fine, 2014). Brain metastases, similarly,
are aggressive tumors that affect 200,000 patients per year in
the United States (Lu-Emerson and Eichler, 2012) and usually
occur late in the clinical course, often heralding end-stage dis-
ease. Treatment options are limited, and survival is measured
inmonths (Owonikoko et al., 2014). AlthoughGBMand brainme-
tastases represent a broad range of cancer subtypes with
distinct cellular origins and diverse genetic programs, they
exhibit common metabolic characteristics that may be the result
of reprogramming to enable rapid growth in the brain. Using 13C-
NMR, we have previously shown in patients with GBM, lung, and
breast cancer brain metastases that these tumors oxidize
glucose in the citric acid cycle (CAC) to producemacromolecular
precursors and energy (Maher et al., 2012). The metabolic
complexity of these tumors is further reflected in the identifica-
tion of a ‘‘bioenergetic substrate gap,’’ whereby a significant
fraction of the acetyl-CoA pool is not derived from blood-borne
glucose (Maher et al., 2012). The striking commonality of this
finding among different grades of gliomas andmetastatic tumors
of diverse cellular origins prompted us to consider the possibility
that an alternate or additional substrate(s) may serve as an
important carbon source for generating CAC intermediates to
support biosynthesis and bioenergetics in vivo.
Although the normal healthy adult brain relies almost exclu-
sively on glucose as the major energy substrate, it can readily
adapt to alternate fuels, including ketone bodies, short and
medium chain fatty acids, and acetate (Ebert et al., 2003).
Astrocytes are capable of supporting neuronal function by
utilizing acetate as a metabolic substrate under conditions of
limiting glucose supply, including diabetic hypoglycemia and
chronic alcohol abuse (Cloughesy et al., 2104; Schurr, 2001;ell 159, 1603–1614, December 18, 2014 ª2014 Elsevier Inc. 1603
Jiang et al., 2013). Because GBMs develop from the astroglial
lineage, we hypothesized that these tumors retain the capacity
to metabolize acetate during transformation. The most common
brain metastases, in contrast, arise from organs that are not
known to utilize substrates other than glucose. We speculated,
that the unique brain microenvironment might drive tumors of
diverse origins to utilize the same metabolic substrates to fuel
aggressive growth. To test this hypothesis in vivo, we used hu-
man orthotopic tumor (HOT) mouse models of GBM and brain
metastases and applied methods in intermediary metabolism
for studyingmultiple substrates using 13C-labeled nutrients (Mal-
loy et al., 1988; Sherry et al., 1992). Coinfusion of 13C-acetate
and 13C-glucose has been used extensively to study normal ro-
dent brain metabolism in which differential handling of acetate
and glucose by the glial and neuronal compartments can be
demonstrated by 13C-NMR of resected brain tissue. These
methods enable direct tracing of the metabolic fate of infused
substrates beyond simple uptake in the cell and therefore can
be used to determine directly whether acetate can be oxidized
by GBM and/or brain metastases in an orthotopic model in vivo.
Here, we report that mice harboring human GBM or brain me-
tastases can completely oxidize acetate in the tumors. We have
validated this finding in patient tumors by infusing 13C-acetate in
patients with GBM, breast cancer, and non-small cell lung can-
cer during surgical resection of their tumors and show that
there is robust labeling of CAC intermediates by blood-borne
13C-acetate.
In the article by Comerford et al. (2014) in this issue of Cell, the
authors demonstrate a critical role for the nucleocytosolic acetyl-
CoA synthetase enzyme, ACSS2, in hepatocellular carcinoma
and broad immunoreactivity for ACSS2 in diverse human tumor
types, including gliomas, breast cancer, and lung cancer. Here,
we show that ACSS2 is upregulated in the HOT and primary hu-
man tumors, as well as a murine glioma model. In ACSS2
knockout mouse embryo fibroblasts (MEFs), 13C-acetate fails
to label CAC intermediates, and in human GBM neurospheres,
stable ACSS2 knockdown leads to failure of self-renewal. These
studies provide a potential mechanistic link between ACSS2 ac-
tivity and in vivo acetate oxidation in tumors.
RESULTS
Glioblastomas Oxidize Acetate in the Citric Acid Cycle
Thehumanorthotopic tumor (HOT) lines ofGBMandbrainmetas-
tases used in this study were each derived from an individual pa-
tient tumor, and implanted into the basal ganglia of NOD-SCID
mice within 3 hr of surgical resection. All mouse experiments
were approved by the Animal Resource Center, University of
Texas Southwestern Medical Center (UTSW). Clinically symp-
tomatic tumors arose within 2–4 months. The tumors, which are
linked to UTSW Institutional Research Board (IRB)-approved
collection of clinical information, were serially passaged and
expanded in the mouse brain without adaptation to cell culture.
Brain-only passaging helps ensure the preservation of the pheno-
typic, molecular and metabolic profiles of the human tumors and
the tumor-stromal interactions, to the extent possible in an exper-
imental system.Weselected sixHOT lines (UT-GBM1-6; TableS1
available online) that are representative of the most common1604 Cell 159, 1603–1614, December 18, 2014 ª2014 Elsevier Inc.GBM molecular profiles (Brennan et al., 2013). Each line was
generated at the time of the patient’s initial diagnosis prior to
any treatment and was studied here in early in vivo passage. A
seventhHOT line (UT-GBM7), generated at the time of repeat sur-
gery for tumor recurrence 15 months after initial resection in the
same patient from which the UT-GBM6 HOT line was derived,
was chosen to compare substrate utilization in the setting of
recurrence and multimodality resistance. We have validated
in vivo that UT-GBM6 is temozolomide (TMZ) sensitive, whereas
UT-GBM7 is TMZ resistant (Sagiyama et al., 2014).
Representative histological sections from UT-GBM1 (Fig-
ure 1A) show an expansive mass (T) comprised of densely
packed tumor cells and infiltration into the brain at the leading
edges. In each mouse, the contralateral hemisphere served as
a matched control for substrate utilization. It is referred to as
‘‘non-tumor bearing brain’’ (NT; Figure 1A) rather than ‘‘normal
brain’’ because the brain surrounding a large tumor is subjected
to mass effect, an increase in reactive astrocytes and diffusible
factors from the tumor and/or blood, conditions which could
potentially impact brain metabolism. 13C-NMR analysis of NT
brain provides a valuable internal control for each mouse
because the NT and T are exposed to the same circulating con-
centrations of 13C-glucose and 13C-acetate and systemic condi-
tion of themouse. Thus, differences in labeling patterns and sub-
strate utilization between NT and T reflect tumor-specific
handling of the substrates.
[1,6-13C]glucose and [1,2-13C]acetate were chosen for coinfu-
sion because oxidation of each substrate produces distinct la-
beling patterns in CAC intermediates, enabling a direct compar-
ison of substrate utilization in a given tissue (Malloy et al., 1988;
Taylor et al., 1996; Deelchand et al., 2009). In the schema (Fig-
ure 1B), metabolism of [1,6-13C]glucose (blue circles) leads to la-
beling of carbon 3 in pyruvate, followed by production of acetyl-
CoA labeled in position 2, which condenses with oxaloacetate
(OAA), leading to labeling of carbon 4 in a-ketoglutarate
(a-KG), glutamate, and glutamine during the first turn of the
CAC, and in carbons 3 and 4with subsequent turns. This labeling
generates a singlet (S) and doublet 3, 4 (D34) in glutamate C4
(GLU4) and glutamine C4 (GLN4) (for example, Figure 1C). In
contrast, metabolism of [1,2-13C]acetate leads to labeling of
both carbons (red circles) of acetyl-CoA with subsequent label-
ing of carbons 4 and 5 of a-KG and glutamate in the first turn
of the CAC, generating a doublet 4,5 (D45) (for example, Fig-
ure 1C). In subsequent turns of the cycle, labeling in carbons 3,
4, and 5 generates a doublet of doublets (quartet, Q) (for
example, Figure 2A). Thus, the 13C-NMRmultiplet pattern in car-
bon 4 of glutamate (GLU4) reflects differential labeling of the
acetyl-CoA pool and provides a direct and unequivocal readout
of substrate metabolism, whereby D45 and Q report acetate
oxidation and S and D34 report glucose oxidation (Sherry
et al., 1992). The fractional amount of each multiplet in GLU4
can be obtained by determining the area of each multiplet rela-
tive to the total spectral area of GLU4, in which the areas of S,
D34, D45, and Q sum to one (Marin-Valencia et al., 2012b).
The NT brain 13C-NMR spectrum (Figure 1C) shows high signal
to noise and well-resolved multiplets arising from 13C-13C
coupling. Oxidation of both glucose and acetate in NT brain is
demonstrated by the presence of S and D34 from glucose and
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Figure 1. Metabolism of Coinfused [1,6-13C]
Glucose and [1,2-13C]Acetate
(A) Low-power hematoxylin & eosin (H&E) images
of a GBM HOT mouse brain at the time of co-
infusion. (a) A large tumor (T) mass is seen in the
right hemisphere. The left hemisphere is desig-
nated nontumor (NT) brain. Scale bar, 3 mm. High-
power images of (b) tumor (T), (c) NT brain (scale
bars, 10 mm), and (d) tumor that infiltrates brain at
the edge of the mass (scale bar, 20 mm).
(B) Schema showing the fate of individual carbons
from infused [1,6-13C]glucose (blue-filled circles,
13C) and [1,2-13C]acetate (red filled circles, 13C)
through the first turn of the CAC and labeling in
a-KG, GLU, and GLN after multiple turns. Open
circles, 12C. Numbers refer to carbon positions.
Abbreviations: LAC, lactate; Ac-CoA, acetyl CoA;
CIT, citrate; a-KG, a-ketoglutarate; GLU, gluta-
mate; GLN, glutamine; OAA, oxaloacetate; PDH,
pyruvate dehydrogenase; LDH, lactate dehydro-
genase; PYR, pyruvate.
(C) 13C-NMR spectrum from NT brain after co-
infusion. Insets are GLU4 and GLN4. Singlet (S)
and doublet 3,4 (D34) in blue are generated from
13C-glucose metabolism, and doublets 4,5 (D45) in
red are generated from 13C-acetate metabolism.
The color scheme is the same in all figures.
Chemical shift assignments are the same in Fig-
ures 2 and 3: 1, alanine C3; 2, lactate C3; 3,
N-acetylaspartate (NAA) C6; 4, gamma-amino-
butyric acid (GABA) C3; 5, glutamine C3; 6, gluta-
mate C3; 7, glutamine C4; 8, glutamate C4; 9,
GABA C2; 10, aspartate C3; 11, GABA C4; 12,
taurine (?); 13, aspartate C2; 14, glutamine C2; 15,
glutamate C2.
See also Table S1.D45 from acetate in GLU4 (Figure 1C, inset). Although the same
multiplets are present in glutamine C4 (GLN4), the pattern of
D45 and D34 is different from that in GLU4, recapitulating the
well-recognized pattern that results from the differential handling
of acetateandglucose inglia andneurons (Taylor et al., 1996). The
13C-NMR tumor spectrum from the samemouse (Figure 2A, inset)
has several notable differences. First, there is a marked increase
in D45 and the presence of Qs, indicating increased oxidation of
acetate in the tumor when compared to the NT brain. Second,
the similaritybetween theGLU4andGLN4 labelingpattern (prom-
inent D45 and small or absent D34) provides evidence that gluta-
mine is being derived from glutamate in the tumor.
To determine the biological variability of acetate utilization
within individual mice with tumors derived from the same
parental line (UT-GBM1), we coinfused an additional four mice.
The resulting 13C-NMR spectral patterns of GLU4 and GLN4 in
NT brain and tumor were almost indistinguishable from the NTCell 159, 1603–1614, Debrain and tumor spectra presented in Fig-
ures 2A and 2B (data not shown). To
quantify the relative contribution of each
substrate to the labeling in GLU4, we
calculated the acetate-to-glucose ratio,
(D45+Q) to (S+D34). This has been used
extensively in brain metabolism, wherethe differential labeling of multiplets enables discrimination of
glial and neuronal metabolism, because astrocytes, but not neu-
rons, are capable of oxidizing acetate (Deelchand et al., 2009;
Marin-Valencia et al., 2012b). In applying this analysis to brain tu-
mors, we assume a single compartment comprised of tumor
cells, based on histological analysis. Thus, the acetate-to-
glucose ratio in tumor GLU4 reflects the relative contribution of
each labeled substrate. The ratio was calculated for the five
mice, NT brain and tumor (Figure 2B).
In NT brain, glucose is the major substrate being oxidized with
anacetate-to-glucose ratio of 15.8%±1.2%to84.2%±1.1%(ra-
tio 0.19 ± 0.02), achieved with 13C-glucose fractional enrichment
of 32% ± 5% in the blood and plasma acetate levels that rose
approximately 4-fold (from 0.177 ± 0.02 mM to 0.619 ±
0.13mM) during infusion. The acetate-to-glucose ratio is remark-
ably similar to that previously reported in normal adult mouse
brain (calculated as 14% to 86%, ratio 0.16; Marin-Valenciacember 18, 2014 ª2014 Elsevier Inc. 1605
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Figure 2. Metabolism of Coinfused [1,6-13C]Glucose and [1,2-13C]
Acetate in GBM versus NT Brain
(A) 13C-NMR GBM tumor spectrum after coinfusion. Inserts are GLU4 and
GLN4. Chemical shift assignments are the same as in Figure 1.
(B) Relative percent labeling of GLU4 by acetate and glucose in five replicates
of NT brain and T fromUT-GBM1. Peak areas inGLU4weremeasured from the
13C-NMR spectra. The contribution of 13C-glucose (S+D34) (blue bars) and
13C-acetate (D45+Q) (red bars) is expressed as a percent of the total peak area
in GLU4.
See also Figure S1 and Table S1.et al., 2012b). The acetate-to-glucose ratio in the five tumors was
51.8% ± 2.9% to 48.3% ± 2.9% (ratio 1.02 ± 0.09), which was 5-
foldhigher than inNTbrain (p<0.001), demonstratinga significant
shift toward acetate oxidation in the tumor.
Direct analysis of the multiplet ratios in GLU4 does not provide
information about the contribution of unlabeled substrates in the
acetyl-CoA pool, which could be playing an important role in
fueling the tumor. To determine the size of the unlabeled pool,
we applied a validated non-steady-state algorithm to the spec-
tral analysis, which takes into account the total multiplet area
in the glutamate C3 and C4 and the levels of infused substrates
in the blood (Malloy et al., 1988, 1990b). The fraction of acetyl-
CoA due to acetate increased from 6.0% ± 1.2% in NT brain to
24.7% ± 2% in the tumor (p < 0.0001). This was associated
with a decrease in the fractional contribution from glucose1606 Cell 159, 1603–1614, December 18, 2014 ª2014 Elsevier Inc.from 75.8% ± 3.7% in NT brain to 50.4% ± 9.1% in the tumor
(p < 0.002), whereas the unlabeled fraction was not significantly
different between NT brain (18.2% ± 4.0%) and tumor (25.5% ±
8.0%, p > 0.05). The decrease in glucose oxidation between NT
brain and tumormay, at least in part, reflect a loss of the neuronal
contribution to glucose utilization.
Having established the reproducibility of biological replicates
in UT-GBM1 that has PDGFR overexpression/PTEN deletion,
we next addressed the question of whether the ability to oxidize
acetate is a function of the dominant oncogenes and/or tumor
suppressor genes in the tumor. Mice from five additional GBM
HOT lines (UT-GBM2-6; Table S1) were coinfused with
[1,2-13C]acetate and [1,6-13C]glucose. The acetate-to-glucose
ratios were calculated for these lines. No differences were found
among the NT brains, and in each line, tumor acetate oxidation
was higher than in NT brain. The relative 13C-acetate contribution
to GLU4 ranged from 18.8% to 52% (32% ± 5%) in the tumor.
Differences in the percent acetate oxidation among the individ-
ual lines could not be attributed to amplification of EGFR or
PDGFRa, presence of the EGFR VIII mutant, loss of PTEN, or
loss of INK4a/ARF (data not shown).
Because all six GBM HOT lines were generated from patient
tumors prior to the initiation of treatment, we next studied the tu-
mor line generated from recurrent tumor (UT-GBM7) and
compared it directly with the initial GBM HOT line from the
same patient (UT-GBM6). Nearly identical labeling patterns in
GLU4 and GLN4 were identified (Figure S1), with dominance of
the D45, an acetate-to-glucose ratio 25% to 75% in the initial tu-
mor (UT-GBM6), and 27% to 73% in the recurrent tumor
(UT-GBM7). The relative avidity for acetate and glucose is
remarkably similar in these tumors that were derived indepen-
dently more than a year apart and after extensive treatment
and acquisition of chemo- and radioresistance.
Brain Metastases from Diverse Cell Types Oxidize
Acetate
To determine whether acetate oxidation is a feature of nonglial
brain tumors, we studied five brain metastasis HOT tumor lines:
breast cancer (estrogen receptor [ER] and progesterone recep-
tor [PR] negative and HER2 positive), non-small cell lung cancer
(no mutations in EGFR, ALK, or KRAS), clear cell renal cell carci-
noma (VHL/), melanoma (BRAFV600E mutated), and endome-
trial cancer, a tumorwhich rarelymetastasizes to the brain. There
is a remarkable preservation of the signature histopathological
and molecular features of the human brain metastases in the
HOT models (see examples in Figure 3). Of note, the breast
and lung cancer HOT lines were generated from the human tu-
mors infused with 13C-glucose during surgery that we reported
previously (Maher et al., 2012), each of which oxidized glucose
but also showed a significant bioenergetic substrate gap. The
study of these tumors here as orthotopic mouse models pro-
vided a unique opportunity to assess metabolic phenotype fidel-
ity in these models.
The 13C-NMR spectral patterns from the five individual tumor
lines and matching NT brains following coinfusion of [1,6-13C]
glucose and [1,2-13C]acetate recapitulated the findings in GBM
with remarkable similarity. Representative GLU4 and GLN4 la-
beling from the breast cancer (Figure 3A) and melanoma
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Figure 3. Oxidation of 13C-Acetate, but Not
13C-Glutamine, in Brain Metastases
(A and B) Coinfusion of [1,6-13C]glucose and
[1,2-13C]acetate in HOT models from breast can-
cer brain metastasis (ER, PR, HER2+) (A) and
melanoma (BRAFV600E mutant) (B). Scale bars,
10 mm. Patient tumor (left) is compared with the
HOT mouse tumor generated from the same pa-
tient tumor (right) for HER2 in breast (A) and
melanin in melanoma (B). The GLU4 and GLN4
13C-NMR profiles from the HOT tumors show
similar labeling patterns with prominent D45
generated from 13C-acetate oxidation. The pres-
ence of S and D34 indicates that 13C-glucose was
oxidized simultaneously. Note the similar pattern in
GLN4 (prominent D45) in both tumor spectra.
(C) Infusion of [U-13C]glutamine in the melanoma
HOT model. Insets are GLU4 and GLN4. Note the
different labeling pattern in GLU4 and GLN4.
Prominent labeling was not detected in aspartate
(C3 in position 10 and C2 in position 13 in the full
spectrum) or malate (MAL) (not labeled).
See also Figure S2 and Table S1.(Figure 3B) reveal prominent D45 consistent with oxidation of ac-
etate, as well as a large singlet (S) and small D34, consistent with
glucose oxidation. The acetate-to-glucose ratio in GLU4 was
calculated for NT brain and tumor. Similar to the GBMs, there
was a significant increase in the fraction of acetate being
oxidized in the tumors, ranging from 21 to 42% (29% ± 3%).
Calculation of the fractional contribution to the acetyl-CoA pool
for these tumors yielded 14.5% ± 3.9% from 13C-acetate,
49.2% ± 5.6% from 13C-glucose and 37% ± 4.3% from the un-
labeled substrate.
Glutamine Is Not Directly Oxidized in the CAC of GBM
and Brain Metastases In Vivo
We have previously shown that GBM HOT tumors do not
oxidize glutamine in the CAC in vivo (Marin-Valencia et al.,
2012c). Here, we examined an additional two GBM HOT lines
to increase the molecular diversity of the lines being examinedCell 159, 1603–1614, Deand three brain metastasis HOT lines
(non-small cell lung cancer, melanoma,
and endometrial cancer) to determine
whether glutamine could be directly
oxidized in these tumors. Nearly identical
spectra were obtained following infusion
of [U-13C]glutamine in the three tumor
lines (Figures 3C, S2A, and S2B) and in
GBM (data not shown). GLN4 was domi-
nated by large Qs, which is consistent
with the presence of 13C-glutamine in
the tumor. The presence of smaller Qs
in GLU4 suggests that there is some
direct exchange of 13C-glutamine with
glutamate. However, the GLU4 in each
tumor was dominated by D45, a pattern
that cannot be produced simply from ex-
change with glutamine. Moreover, prom-inent Qs in malate and aspartate were not visible in the spectra
(Figures 3C and S2), as would have been expected if [U-13C]
glutamine had exchanged with glutamate, which then
exchanged with a-KG and subsequently was fully oxidized in
the CAC. An alternative route for GLU4 13C labeling in the tu-
mor was more likely than direct glutamine oxidation. The multi-
plet patterns in lactate and alanine from liver, NT brain, and tu-
mor from the lung brain metastasis HOT line (Figure S2B) are
consistent with production of 13C-glucose from infused
[U-13C]glutamine outside the CNS, likely in the liver, with sub-
sequent 13C-glucose oxidation in NT brain and tumor. This is
supported by the presence of 13C-labeled glucose in the liver
13C-NMR spectrum (Figure S2C). Taken together, the labeling
patterns in the HOT GBM and brain metastasis tumors
following infusion of [U-13C]glutamine further extends our previ-
ous finding in GBM that glutamine is taken up by the tumors
but is not directly oxidized in the CAC in vivo.cember 18, 2014 ª2014 Elsevier Inc. 1607
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Figure 4. Immunoreactivity to ACSS2 Is Correlated with Glioma
Grade and Survival of Grade II and II Gliomas
(A) Representative sections from glioma TMA showing the range of ACSS2
staining. Low, fewer than 50% of tumor cells are positive, and intensity of
staining is one (scale 0–3); moderate, 75% positive, intensity 1–3; high, 100%
positive and intensity 2–3.
(B) Box and whisker plot of ACSS2 histoscore for WHO grades II, III, and IV
gliomas. **grade II versus grade IV (p < 0.001), and *grade III versus grade IV
(p < 0.01).
(C) Kaplan-Meier curve of grade II and III astrocytomas and oligoas-
trocytomas. High versus low ACSS2 staining (n = 25 each group) based on the
median histoscore. **p < 0.001.
See also Figure S3A.ACSS2 Upregulation Is Associated with More
Aggressive Disease in Glioma
ACSS2 is a critical enzyme for converting acetate to acetyl-CoA
in murine models of liver cancer (Comerford et al., 2014) and was
assessed here for a potential role in acetate metabolism in brain
tumors. ACSS2 immunohistochemistry (IHC) showed moderate
to high expression in 6 of 7 GBM and all brain metastasis HOT
lines (Figure S3). It was notable that the GBM with the lowest1608 Cell 159, 1603–1614, December 18, 2014 ª2014 Elsevier Inc.fractional acetate oxidation (18%) had the lowest ACSS2
expression by IHC (histoscore = 50). ACSS2 expression in our
clinically annotated glioma tissue microarray (TMA) was variable
(Figure 4A) but significantly higher in GBM than the grade II and II
gliomas (Figure 4B). Among the grade II and III gliomas, shorter
survival time was associated with higher ACSS2 staining (Fig-
ure 4C). ACSS1, ACSS3, sterol regulatory element binding pro-
tein (SREBP-1) expression in the TMA was not correlated with
ACSS2 expression or with survival in any of the clinical sub-
groups (data not shown).
To determine whether ACSS2 has a direct impact on GBM
growth, primary neurosphere cultures derived from two indepen-
dent GBM HOT lines were infected with retroviruses expressing
a small hairpin RNAi (shRNAi)-targeting ACSS2 for knockdown
(KD) or a scrambled shRNAi (SCR) for control. Comerford et al.
(2014) have extensively characterized these retroviruses. Infec-
tion with ACSS2-KD shRNAi, but not SCR, resulted in cell death
(Figure 5A). Surviving GBMcells failed to form neurospheres (2%
± 0.5% versus 23% ± 4%, p < 0.001) and thus could not be as-
sessed for in vivo tumorigenicity.
ACSS2 Expression Is Associated with Transformation
and Enables 13C-Acetate Incorporation into Glutamate
Next, we investigated whether ACSS2 has a potential role in gli-
oma tumorigenicity. Primary astrocyte cultures were generated
from multiallele conditional mice carrying glioma-relevant muta-
tions (p53f/f, PTENf/f, and LSLBRAF
V600E) that activate the PI3K/
AKT andMAPK/ERK pathways. In this ex vivomodel, successive
accumulation of mutations was associated with increased
ACSS2 expression, with the triple-mutant cells, p53/
PTEN/BRAFV600E, having the highest expression (Figure 5B).
High-grade gliomas generated from intracranial implantation of
the triple-mutant cells were able to oxidize acetate when coin-
fused with 13C-acetate and 13C-glucose (Figure 5C). It is notable
that, in contrast to the tumor suppressor-deficient, immortalized
primary astrocytes, wild-type (WT) astrocytes markedly downre-
gulated expression of all ACSS enzymes under standard culture
conditions (Figure 5D), making it an unreliable experimental sys-
tem for further in vitro acetate metabolic studies.
To determine whether there is a direct mechanistic link
between ACSS2 and oxidation of 13C-acetate, we investigated
the extent of 13C-acetate incorporation into glutamate in
ACSS2 KO MEFs. The KO MEFs exhibited very little incorpora-
tion of 13C-acetate into glutamate, whereas reintroduction of
the WT ACSS2 gene into these cells significantly increased ace-
tate incorporation into glutamate (Figure S3). This direct genetic
gain-of-function experiment provides a compelling link between
ACSS2 and acetate oxidation in the CAC.
13C-Acetate Is Oxidized in Patient Brain Tumors
To validate in humans the finding that acetate can be oxidized in
the orthotopic models, we next infused [1,2-13C]acetate in four
patients (two GBM, one breast cancer brain metastasis, and
one non-small cell lung cancer brain metastasis) during surgical
resection of their tumors. Despite the diversity of tumor types,
nearly identical 13C-NMR spectra with excellent signal-to-noise
ratio and robust labeling in glutamate and glutamine were ob-
tained in the four tumors (Figures 6, 7, and S4). The dominance
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Figure 5. Expression of ACSS2 Is Linked to
GBM Growth and Malignant Potential
(A) Comparison of primary GBM cultures infected
with retroviruses expressing ACSS2 shRNAi (KD)
or scrambled shRNAi (SCR). Two independent
cultures are shown. Neurospheres are visible in
the SCR, cultures but not in KD cultures. Scale
bars, 250 mm.
(B) Fold change (qRT-PCR) of ACSS1 and ACSS2
mRNA in primary conditional (floxed) astrocyte
cultures after infection with adenocre to produce
(a) p53/, (b) p53/, PTEN/, (c) p53+/,
PTEN/,BRAFV600E, and (d) p53/, PTEN/,
BRAFV600E. *p < 0.01 versus b or c; **p < 0.001
versus a.
(C) Glutamate C4 multiplets from 13C-NMR spec-
trum of an intracranial tumor arising from p53/,
PTEN/, and BRAFV600E astrocytes after co-
infusion of 13C-acetate and 13C-glucose.
(D) Fold change (qRT-PCR) of ACSS1 and ACSS2
mRNA in primary astrocytes in culture at passages
2 (P2), 5 (P5), and 6 (P6). *p < 0.01; **p < 0.005
versus P2.
See also Figure S3B.of the D45 and presence of quartets (Q) in GLU4 and GLN4 is
direct evidence that acetate was oxidized in the CAC. Moreover,
the same multiplet pattern in glutamine demonstrates that this
metabolite was generated from glutamate that had originated
as blood-borne acetate. 13C-acetate enrichment in the blood
was 88.5% ± 6.4%. Less than 3% (2.4% ± 1.1%) 13C-glucose
was recovered in the blood, demonstrating that the labeling in
the tumors was not due to 13C-glucose production outside the
CNS. The fractional contribution of [1,2-13C]acetate to the
acetyl-CoApool in the four tumorswas 47.8%± 3.8%.Unlabeled
substrate accounted for 51.3% ± 2.6% of the acetyl-CoA pool,
with 1.7% ± 0.4% coming from [2-13C]acetate, consistent with
natural abundance 13C. The unlabeled fraction is likely due in
large part to circulating glucose, based on data fromour previous
study of brain tumor patients infused with 13C-glucose (Maher
et al., 2012) and the ability of the orthotopic mouse tumors to
co-oxidize glucose and acetate. ACSS2 immunoreactivity
ranged from moderately to strongly positive in the four tumors
with specificity demonstrated in the lung brain metastasis (Fig-
ure 7), where tumor, but not surrounding stroma, is labeled.Cell 159, 1603–1614, DeDISCUSSION
Determining the carbon source(s) for
biosynthesis and bioenergetics in
rapidly proliferating tumors in vivo repre-
sents a critical step toward identifying
potential vulnerabilities for therapeutic
targeting. Our initial 13C-NMR data
from 13C-glucose infusion in brain tumor
patients (Maher et al., 2012) demon-
strated a complex metabolic tumor
phenotype that had not previously
been reported; excess production of
lactate (the Warburg effect) occurringsimultaneously with CAC oxidation of glucose as well as oxida-
tion of another unidentified substrate(s), termed the ‘‘bioener-
getic substrate gap.’’ Here, we show that brain tumors from
widely diverse cellular origins have the capacity to oxidize
infused 13C-acetate. This finding in GBMs is perhaps not sur-
prising given that glial cells, the presumptive GBM cells of
origin, are well known to be capable of oxidizing acetate.
This suggests that, despite the extensive molecular reprog-
ramming that is a hallmark of GBM, the ability to oxidize ace-
tate is preserved, if not enhanced, in the tumors. 11C-acetate
positron emission tomography (PET) positivity has been re-
ported in gliomas (Yamamoto et al., 2008), consistent with
our finding that acetate is actively taken up by the proliferating
tumor cells. Nutrient uptake, however, although being of signif-
icant clinical utility as an imaging biomarker, provides no infor-
mation about entry of the nutrient into specific metabolic path-
ways. A major advantage of 13C-NMR, as demonstrated here,
is that there are multiple internal controls within a single spec-
trum for examination of the relative activity of specific meta-
bolic pathways. For example, the pyruvate pool is read outcember 18, 2014 ª2014 Elsevier Inc. 1609
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Figure 6. Oxidation of [1,213C]-Acetate in a
Patient with GBM
(A) Preoperative sagittal image from gadolinium-
enhanced MRI shows a large enhancing tumor in
the left frontotemporal region (arrow).
(B) Strong ACSS2 immunoreactivity in the tumor.
Scale bar, 10 mm.
(C) 13C-NMR spectrum with GLU4 and GLN4 in-
sets. Note the prominent D45 and Qs reflecting
robust 13C-acetate oxidation. Abbreviations are
the same as in Figure 2. Chemical shift assign-
ments are the same in Figure 7: 1, alanine C3; 2,
lactate C3; 3, NAA C6; 4, acetate C2; 5, unas-
signed; 6, glutamine C3; 7, glutamate C3; 8,
unassigned; 9, glutamine C4; 10, glutamateC4; 12,
NAA C3; 16, glutamine C2; 17, glutamate C2.by labeling in lactate and alanine, whereas the acetyl-CoA pool
is read out by labeling in glutamate.
The finding that brain metastases from a wide spectrum of
cellular origins alsooxidize acetate, however,wasnot anticipated
because organs that most frequently give rise to tumors that
metastasize to the brain (lung, breast, kidney, and melanoma)
are not known to show significant 11C-acetate uptake on PET.
The data suggest that the ability to oxidize acetate is either a
unique adaptation to the brain microenvironment or a more gen-
eral property of tumor cells. In support of the latter possibility,
several non-CNS tumors, including hepatocellular and prostate
cancer, show avid differential 11C-acetate uptake on PET relative
to the normal organ (Ho et al., 2003; Oyama et al., 2002).
‘‘Co-oxidation’’ of acetate and glucose was seen in all of the
GBM and brain metastasis HOT models, raising the possibility
that substrate co-oxidation might be an adaptive mechanism1610 Cell 159, 1603–1614, December 18, 2014 ª2014 Elsevier Inc.in rapidly proliferating tumors. It would
ensure the availability of an adequate
pool of carbons to generate CAC interme-
diates and support the high bioenergetic
demands of growth while a large fraction
of the glucose is being diverted to lactate.
In this study there was no evidence of
direct 13C-glutamine oxidation in the or-
thotopic models, which may reflect differ-
ential substrate handling in brain tumors.
Normal plasma acetate levels in non-
fasted humans range between 0.05 mM
(Tollinger et al., 1979) and 0.18 mM
(Skutches et al., 1979). Under normal
resting conditions, circulating acetate
levels may contribute up to 10%–15% of
the basal energy demands of brain astro-
cytes (Dienel and Cruz, 2006). Circulating
free acetate is generated by fermentation
of carbohydrates in the gut by commensal
anaerobes and by the liver under keto-
genic conditions (low glucose) as a final
product of fatty acid oxidation or by
ethanol metabolism in heavy drinkers
(Jiang et al., 2013). It has recently been re-ported that 3 hr after oral administration of 13C-inulin to mice,
doublets of C4 glutamate and glutamine can be clearly resolved
in brain by high-resolution magic angle spinning MR spectros-
copy from brain uptake of circulating 13C-labeled acetate (Frost
et al., 2014). Moreover, the relative contribution of acetate to
brain metabolism has been shown to increase following brain
injury, which limits glucose oxidation (Bartnik-Olson et al.,
2010). This finding may be analogous to brain tumor regions
with a paucity of active neurons and limited PDH activity as a
result of intratumoral hypoxia. Taken together, there is clear
evidence that normal circulating acetate levels may be adequate
to contribute to the metabolic demands of the tumor.
In order for the tumor cell to metabolize acetate, the cell must
upregulate ACSS2, the enzyme critical for converting acetate to
acetyl-CoA, as shown in hepatocellular carcinoma in the accom-
panying manuscript (Comerford et al., 2014). The increased
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Figure 7. Infusion of [1,213C]Acetate in a
Patient with a Non-Small Cell Lung Cancer
Brain Metastasis
(A) Preoperative MRI sagittal image shows a gad-
olinium-enhancing tumor in the left cerebellum
(yellow arrow) with a cystic component (orange
arrow).
(B) Moderate ACSS2 immunoreactivity in the tu-
mor (T) with a lack of staining in the surrounding
stroma (S). Scale bar, 10 mm.
(C) 13C-NMR spectrum with GLU4, GLN4, and
ASP3 insets. Abbreviations are the same as in
Figure 2. Chemical shift assignments are the same
as in Figure 6, with the following additions: 11,
aspartate C3; 13, glycine C2; 14, alanine C2; 15,
aspartate C2.
See also Figure S4 for 13C-spectra from two
additional patient tumors.expression of ACSS2 in GBMwhen compared to the lower grade
gliomas supports the assertion that upregulation of this enzyme
is linked to an increase in acetate oxidation by the tumor. Higher
expression of ACSS2 is associated with shorter survival among
the patients with grade II and III gliomas, potentially identifying
tumors that are destined to transform to grade IV (GBM) more
rapidly.
GBM neurospheres have been shown to be critically depen-
dent on oxidative phosphorylation, but not on inhibition of glycol-
ysis (Janiszewska et al., 2012). This finding is consistent with our
observation that inhibition of ACSS2 in the GBM neurospheres
results in lossof clonogenicity andcell death andsupports thehy-
pothesis that ACSS2 is important for supporting GBM viability.
Moreover, the data from thegenetically engineered gliomamodel
show that mutations that drive AKT and ERK pathways (loss of
PTEN and constitutive BRAFV600E activation) converge to in-
crease ACSS2 expression (Figure 5). The most direct link be-
tween the enzyme and the cell’s ability to oxidize acetate in the
CAC was shown in ACSS2 null MEFs. Although this is a differentCell 159, 1603–1614, Desystem than glial cells, the finding that
labeled glutamate from 13C-acetate
increased markedly in a time-dependent
manner in ACSS2 null MEFS when the
WTACSS2was reintroduced into the cells
is consistent with the wide range of tumor
cell types that are able to oxidize acetate.
Recent evidence suggests that in order
for tumor cells to adapt to the brain micro-
environment, they must undergo unique
genetic adaptations (Valiente et al.,
2014). In view of this formidable challenge,
identification of a potentially druggable
target, such as ACSS2, which appears to
have little known function in normal cells,
offers unique advantages in therapy
development. The current work and that
of Comerford et al. (2014) underscores
the value of in vivo studies in cancermeta-
bolism. Having orthotopic tumor modelsof both GBM and a wide range of brain metastases that have
been vigorously cross-validatedwithhumandatawill enable rapid
in vivo workup of novel small-molecule inhibitors that target ace-
tate metabolism, such as ACSS2. In addition, the feasibility of the
13C-nutrient methodology in patients enables a host of follow-up
questions to be addressed from this work, including whether the
ability to oxidize acetate is a property of early-stage tumors or
of the acquisition of metastatic potential. Rapid translation is a
critical need for patients suffering from GBM and brain metasta-
ses, where prognosis is measured in months.
EXPERIMENTAL PROCEDURES
Generation of HOT Mouse Models of GBM and Brain Metastases
Generation of the HOT models of GBM and brain metastases have been pre-
viously described (Marin-Valencia et al., 2012a). Briefly, tumor samples were
obtained from patients at UTSW Medical Center at the time of craniotomy
and tumor resection after written informed consent under an IRB-approved
clinical protocol. All brain metabolic labeling experiments were performed in
awake, alert mice following placement of an indwelling jugular venouscember 18, 2014 ª2014 Elsevier Inc. 1611
catheter. For the isolation of tumor and NT brain regions, thewhole brains were
cut into 1 mm coronal sections. The sections were then microdissected to
minimize contamination of tumor and NT regions.
Primary Cell Cultures
Primaryastrocyte cultureswereculturedaspreviouslydescribed (Bachooet al.,
2002). They were isolated from genetically engineered, multiallele conditional
mice with the following mutations as single or combination (p53f/f, PTENf/f,
and LSLBRAF
V600E). Primary GBM neurospheres were isolated and maintained
under standard neurosphere culture conditions.
Infusions of 13C-Labeled Nutrients and Dissection of Brains and
Tumors
Mouse Studies
Tracer studies in the HOT mice were performed as previously described
(Marin-Valencia et al., 2012c). Mice were infused with [1,6-13C] glucose
(1-13C, 99% enriched; 6-13C, 99% enriched; Sigma-Aldrich Isotec) and
[1,2-13C] acetate (1-13C, 99% enriched; 2-13C, 99% enriched; Cambridge
Isotope Laboratories) as a bolus of 0.3 mg/g of body weight for each tracer
(in 0.3 ml of saline) infused over 1 min, followed by a continuous infusion of
0.0069 mg/g of body weight/min for each tracer (in 0.431 ml of saline) at
150 ml/hr for 150 min. For the experiments using glutamine, mice were infused
with [U-13C] glutamine (95% enriched; Sigma-Aldrich Isotec) as a bolus of
0.28 mg/g of body weight for the tracer (in 0.3 ml of saline) infused over
1 min, followed by a continuous infusion of 0.005 mg/g of body weight/min
(in 0.45 ml of saline) at 150 ml/hr for 180 min.
Human Studies
Patients were enrolled in a UTSW IRB-approved protocol to infuse 13C-iso-
topes (glucose and acetate). For [1,2-13C]acetate infusion, patients were
dosed with 6 mg/kg/min for 5 min, followed by 3 mg/kg/min for 2–3 hr. Patient
recruitment and consent, as well as blood and tumor sampling, have been pre-
viously described (Maher et al., 2012).
13C-NMR Spectroscopy
Proton-decoupled 13C-spectra of tumor and NT brain extracts were acquired
at 150MHz for 13C on Agilent VNMRS Direct Drive Console using 3mm broad-
band NMR probe (Agilent Technologies). Various 13C resonances were as-
signed based on chemical shift position referenced to the lactate C3 singlet
at 20.8 ppm. Relative peak areas of the multiplets were obtained using ACD
NMR Processor as previously described (Maher et al., 2012; Malloy et al.,
1987, 1990a).
IHC
Paraffin-embeddedGBMand brainmetastasis specimenswere obtained from
the Division of Neuropathology at UTSW. Formalin-fixed paraffin-embedded
(FFPE) 4 mm sections were used for IHC. The primary antibodies and their di-
lutions were as follows: rabbit monoclonal ER (Ventana, cat# 790-4325, 1:100
dilution), rabbit monoclonal PR (Ventana, cat# 790-4296, 1:200 dilution), rabbit
monoclonal HER-2/neu (Ventana, cat# 790-2991, 1:200 dilution), and rabbit
polyclonal ACSS2 (Cell Signaling, cat# 3658S, 1:200 dilution).
RNA Isolation, cDNA Preparation, and Quantitative PCR
RNA was isolated from cells in culture using an RNA Isolation Kit (QIAGEN
RNeasy Mini Kit), following the manufacturer’s protocol. cDNA was generated
using the iScript cDNA Synthesis Kit (BioRad). Quantitative real-time PCR us-
ing iTaq SYBR Green Supermix with ROX (Bio-Rad) was performed on a Ste-
pOnePlus Real-Time PCR Systems (Applied Biosystems).
Molecular Analysis
DNA was prepared in accordance with standard methods, and quantitative
PCR for EGFR, ALK, BRAF V600E, PTEN, p16, and p19 was done with stan-
dard primer sets for these genes.
Plasma Acetate Measurement
Plasma acetate was measured using standard manufacturer protocols
(Biovision Colorimetric Assay Kit, cat# K658). Briefly, 1 ml of the diluted clear
filtrate plasma was used for experimental samples. The reaction was per-1612 Cell 159, 1603–1614, December 18, 2014 ª2014 Elsevier Inc.formed at room temperature for 40 min, and an optical reading was taken at
450 nm using spectrophotometer. The unknown sample concentration was
calculated from the standard curve.
Metabolite Extraction and Liquid Chromatography-Tandem Mass
Spectrometry
Cells were seeded on 6 cm plate to 70%–80% confluency. After two washes in
PBS, cells were cultured with glutamine starvation medium (Dulbecco’s modi-
fied Eagle’s medium without glucose and glutamine [cat # D5030, Sigma-
Aldrich], 3.7 g/l sodium bicarbonate, 5.9 g/l HEPES, 20 mM glucose, 10%
FBS), 2 mM sodium [1,2-13C]acetate (cat# CLM-440-1; Cambridge Isotope
Laboratories) was added to the cells, and metabolites were extracted 0, 0.5,
1, 2 hr after acetate addition. After washing with ice-cold PBS, 500 ml of ice-
cold 50% high-performance liquid chromatography-grade methanol was
added to the cells. The plate was floated on liquid nitrogen immediately until
the methanol was frozen. The plate was removed from the liquid nitrogen
and scraped until the methanol was thawed. The suspension was then passed
through ten freeze/thaw cycles using a bead beater and liquid nitrogen and
then centrifuged at 16,000 g at 4C for 10 min. Supernatants were transferred
to a new tube and dried down. Metabolites were resuspended in 140 ml TBA
buffer (5 mM tributylammonium acetate [pH 5.0]) and vortexed for 15 min.
The solution was placed on ice for 30 min and then centrifuged at max speed
for 5 min. The supernatants were transferred to a new tube, placed on ice for
30 min, and then centrifuged at max speed for 5 min. The supernatants were
then processed for liquid chromatography-tandem mass spectrometry anal-
ysis as described previously using a water/methanol gradient with TBA as
the ion pairing agent. A negative mode method targeting labeled glutamate
was established based on examining the pattern of incorporation of labeled
acetate carbons into glutamate, via entry of cytosolic acetyl-CoA into the
TCA cycle. Analysis of the MS/MS fragmentation pattern for glutamate estab-
lished two MRM pairs (148/103 and 148/130) for detection of [1,2-13C]acetate
conversion to M+2 glutamate (Tu et al., 2007).
Retroviral Studies
ACSS2-shRNA-expressing retroviral plasmid with a puromycin selection gene
was used for knockdown studies. We used a scrambled shRNA as control.
Retroviral-containing media was obtained from transfected 293T cells and
added to GBM cells, followed by puromycin selection.
Statistical Analysis
All pooled results are reported as mean ± SEM. For the evaluation of the ace-
tate-to-glucose ratio between tumor and NT brain, a paired t test was used,
and results are reported as mean ± SEM.
For ACSS2 IHC evaluation, the immunostained TMA slides were scored
manually by assigning to each core a value for ACSS2 staining intensity on a
scale of 0–3 and a value representing the proportion of tumor cells staining
on a scale of 0%–100%. These two values (intensity and percent positive cells)
were then multiplied to obtain a histoscore (range, 0–300), which was used in
further analyses. ACSS2 histoscores were dichotomized to high and low at the
median. Kaplan-Meier survival curves were generated and compared with
the Mantel-Cox (log rank) test using GraphPad Prism (v. 6.01) software
(GraphPad).
For further details, please refer to the Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, four
figures, and one table and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2014.11.025.
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